US2014296179A1PendingUtilityA1
Nutritional composition comprising immunoglobulins and oligosaccharides
Est. expiryAug 24, 2024(expired)· nominal 20-yr term from priority
Inventors:Günther BoehmLaura M'RabetBernd StahlJohan GarssenAntony William ScammellRaymonde Peter Peeters
A61P 31/18A61P 31/14A61P 31/12A61P 31/00A61P 3/02A61P 25/00A61P 3/10A61P 11/00A61P 1/00A23L 33/40A61K 39/42A23L 33/12A61K 31/202A61K 35/741A23L 33/21A23V 2002/00A61K 31/702A61K 31/733A23L 1/296A23V 2400/519
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A method of reducing the incidence of respiratory tract infection episodes comprising administering to an infant mammal in need thereof a liquid infant formula composition comprising:
(a) 0.5-10 grams transgalactooligosaccharide per 100 grams dry weight of the composition; and (b) 0.5-10 grams fructopolysaccharide per 100 grams dry weight of the composition.
2 . The method of according to claim 1 , wherein the composition comprising:
(a) 2-5 grams transgalactooligosaccharide per 100 grams dry weight of the composition, and (b) 1-5 grams fructopolysaccharide per 100 grams dry weight of the composition.
3 . The method of according to claim 1 , wherein the composition, as a percentage of the total caloric value of the composition, comprises:
(a) 35-50% energy fat; (b) 7.5-12.5% energy protein; (c) 40-55% energy carbohydrate.
4 . The method of according to claim 3 , wherein at least 50%, by weight, of the carbohydrate of the composition is lactose.
5 . The method of according to claim 3 , wherein the fat, carbohydrate, or protein is of plant, non-human animal, bacterial, or synthetic origin.
6 . The method according to claim 1 , wherein the composition comprises indigestible dextrins, xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligosaccharides, fucooligosaccharides, fructans, fructooligosaccharide, hydrolysed inulin, inulin, or lactose.
7 . The method according to claim 6 , wherein the composition comprises a fructan, fructooligosaccharide, a hydrolysed inulin or an inulin.
8 . The method according to claim 1 , wherein the composition comprises a long chain polyunsaturated fatty acid (LC-PUFA).
9 . The method according to claim 8 , wherein the LC-PUFA is selected from the group consisting of eicosapentaenoic acid (EPA, n-3), docosahexaenoic acid (DHA, n-3) and arachidonic acid (AA, n-6).
10 . The method according to claim 1 , wherein the mammal is a human.
11 . The method according to claim 1 , wherein the composition is administered orally.
12 . The method according to claim 10 , wherein the human is an infant with the age between 0 and 4 years.
13 . The method according to claim 12 , wherein the infant is under 1 year of age.
14 . A method of reducing the incidence of respiratory tract infection episodes comprising administering to an infant mammal in need thereof a liquid infant formula composition supplemented with:
(a) 0.5-10 grams transgalactooligosaccharide per 100 grams dry weight of the composition; and (b) 0.5-10 grams fructopolysaccharide per 100 grams dry weight of the composition.Join the waitlist — get patent alerts
Track US2014296179A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.